Purpose: This study aimed to investigate the expression of NOR1 in hepatocellular carcinoma (HCC) tissue and its relationship with prognosis.
Methods: A sample of 60 specimens including HCC and adjacent normal tissues were collected from postoperative HCC patients from February to September 2011. Immunohistochemistry was used to detect the positive expression of the oxidored-nitro domain containing protein 1 (NOR1), the postoperative disease-free survival (DFS) rate and then the overall survival (OS) was analyzed by the Kaplan-Meier method.
Results: The results showed significantly lower expression of NOR1 in HCC tissue than that in adjacent normal tissue. Moreover, the OS and DFS rate of NOR1 (++) patients were significantly higher than those of other groups.
Conclusion: Consequently, NOR1 is a protective protein in HCC, and the increase of its expression is favorable for the prognosis of patients.
Download full-text PDF |
Source |
---|
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFJ Clin Psychiatry
January 2025
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan, Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
Although antipsychotics are used commonly for delirium, they increase the risk of mortality in elderly patients and those with dementia. As hydroxyzine has sedative and anxiolytic effects, it can be used in the treatment of delirium. We performed a retrospective study to compare the effects of intravenous hydroxyzine and haloperidol monotherapy on delirium.
View Article and Find Full Text PDFJ Neuropathol Exp Neurol
January 2025
Neurotraumatology and Subarachnoid Hemorrhage Research Unit, Area 8: Neurosciences and Mental Health, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Chitinase 3-like protein 1 (CHI3L1) is emerging as a promising biomarker for assessing intracranial lesion burden and predicting prognosis in traumatic brain injury (TBI) patients. Following experimental TBI, Chi3l1 transcripts were detected in reactive astrocytes located within the pericontusional cortex. However, the cellular sources of CHI3L1 in response to hemorrhagic contusions in human brain remain unidentified.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Cardiology, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Background: Both dietary magnesium and serum magnesium are associated with the prognosis of diabetic patients. However, the impact of the magnesium depletion score (MDS), which assesses systemic magnesium deficiency, on the prognosis of diabetic patients remains unclear. This cohort study aims to explore the potential association between the MDS and all-cause and cardiovascular mortality in diabetic patients.
View Article and Find Full Text PDFRheumatology (Oxford)
January 2025
Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.
Objectives: To assess the lung involvement in patients with Still's disease, an inflammatory disease assessing both children and adults. To exploit possible associated factors for parenchymal lung involvement in these patients.
Methods: A multicentre observational study was arranged assessing consecutive patients with Still's disease characterized by the lung involvement among those included in the AIDA (AutoInflammatory Disease Alliance) Network Still's Disease Registry.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!